Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation

Liver Transplantation

Volumn 21, Issue 11, 2015, Pages 1340-1346

  Shaffer, Katherine M ^a   Parikh, Mehul R ^a   Runge, Thomas M ^a   Perez, Sebastian D ^a   Sakaria, Sonali S ^a   Subramanian, Ram M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CREATININE; GADOBENATE DIMEGLUMINE; CONTRAST MEDIUM; GADOBENIC ACID; GADOLINIUM; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CAUCASIAN; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; KIDNEY FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COMPLICATION; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; PROCEDURES; RENAL INSUFFICIENCY; REPRODUCIBILITY; WATCHFUL WAITING;

CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; WATCHFUL WAITING;

EID: 84942630847     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24118     Document Type: Article

References (31)

1. Ginès P, Schrier RW,. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290.
2. Garcia-Tsao G, Parikh CR, Viola A,. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077.
3. Dani G, Sun MR, Bennett AE,. Imaging of liver transplant and its complications. Semin Ultrasound CT MR 2013; 34: 365-377.
4. Waybill MM, Waybill PN,. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001; 12: 3-9.
5. Morcos SK, Thomsen HS, Webb JA,. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999; 9: 1602-1613.
6. Lancelot E, Idée JM, Couturier V, Vazin V, Corot C,. Influence of the viscosity of iodixanol on medullary and cortical blood flow in the rat kidney: a potential cause of nephrotoxicity. J Appl Toxicol 1999; 19: 341-346.
7. Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B,. Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 2009; 15: 1459-1464.
8. Moos SI, van Vemde DN, Stoker J, Bipat S,. Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: A meta-analysis. Eur J Radiol 2013; 82: e387-e399.
9. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW,. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
10. Dong M, Jiao Z, Liu T, Guo F, Li G,. Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials. J Nephrol 2012; 25: 290-301.
11. Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al., Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010; 256: 806-816.
12. Penfield JG, Reilly RF Jr,. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 2007; 3: 654-668.
13. Rieger J, Sitter T, Toepfer M, Linsenmaier U, Pfeifer KJ, Schiffl H,. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 2002; 17: 824-828.
14. Townsend RR, Cohen DL, Katholi R, Swan SK, Davies BE, Bensel K, et al., Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 2000; 36: 1207-1212.
15. Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G,. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 2009; 250: 618-628.
16. Ergün I, Keven K, Uruç I, Ekmekçi Y, Canbakan B, Erden I, Karatan O,. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006; 21: 697-700.
17. Sam AD 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS,. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003; 38: 313-318.
18. Erley CM, Bader BD, Berger ED, Tuncel N, Winkler S, Tepe G, et al., Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 2004; 19: 2526-2531.
19. Heinrich MC, Kuhlmann MK, Kohlbacher S, Scheer M, Grgic A, Heckmann MB, Uder M,. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Radiology 2007; 242: 425-434.
20. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, Schick F,. Relaxivity of gadopentetate dimeglumine (magnevist), gadobutrol (gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213-221.
21. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB,. MR contrast agents for liver imaging: what, when, how. Radiographics 2006; 26: 1621-1636.
22. Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, et al., Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31: 440-446.
23. Becker-Weidman DJ, Kalb B, Sharma P, Kitajima HD, Lurie CR, Chen Z, et al., Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging - comparison to prior same-center results after MR systems improvements. Radiology 2011; 261: 824-833.
24. Bruix J, Sherman M,; for American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
25. Schuppan D, Afdhal NH,. Liver cirrhosis. Lancet 2008; 371: 838-851.
26. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, et al., Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8: 749-761.
27. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P,. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513-523.
28. Finn JP, Kane RA, Edelman RR, Jenkins RL, Lewis WD, Muller M, Longmaid HE,. Imaging of the portal venous system in patients with cirrhosis: MR angiography vs duplex Doppler sonography. AJR Am J Roentgenol 1993; 161: 989-994.
29. Briguori C, Colombo A, Airoldi F, Melzi G, Michev I, Carlino M, et al., Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 2006; 67: 175-180.
30. Akgun H, Gonlusen G, Cartwright J Jr, Suki WN, Truong LD,. Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 2006; 130: 1354-1357.
31. Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, et al., Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 2013; 23: 1250-1259.